Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.

ABSTRACT:

Importance

There is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and efficacy. Moreover, none of the case series from the United States (US) of these potential complications have been population-based.

Objectives

To estimate the reporting rates of myocarditis and pericarditis in the US using the Vaccine Adverse Event Reporting System (VAERS), and to assess if these adverse events were disproportionally reported among the different COVID-19 vaccines.

Design setting and participants

All cases of myocarditis and pericarditis from VAERS reported up to July 28, 2021.

Exposure

Single-d

SUBMITTER: Pareek M 

PROVIDER: S-EPMC10704142 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature